Literature DB >> 34553437

Expanding the family of extracellular chaperones: Identification of human plasma proteins with chaperone activity.

Nicholas J Geraghty1,2, Sandeep Satapathy1,3, Megan Kelly1,4, Flora Cheng5, Albert Lee5, Mark R Wilson1,2.   

Abstract

Proteostasis, the balance of protein synthesis, folding and degradation, is essential to maintain cellular function and viability, and the many known intracellular chaperones are recognized as playing key roles in sustaining life. In contrast, the identity of constitutively secreted extracellular chaperones (ECs) and their physiological roles in extracellular proteostasis is less completely understood. We designed and implemented a novel strategy, based on the well-known propensity of chaperones to bind to regions of hydrophobicity exposed on misfolding proteins, to discover new ECs present in human blood. We used a destabilized protein that misfolds at 37°C as "bait" to bind to potential ECs in human serum and captured the complexes formed on magnetic beads. Proteins eluted from the beads were identified by mass spectrometry and a group of seven abundant serum proteins was selected for in vitro analysis of chaperone activity. Five of these proteins were shown to specifically inhibit protein aggregation. Vitronectin and plasminogen activator-3 inhibited both the in vitro aggregation of the Alzheimer's β peptide (Aβ1-42 ) to form fibrillar amyloid, and the aggregation of citrate synthase (CS) to form unstructured (amorphous) aggregates. In contrast, prothrombin, C1r, and C1s inhibited the aggregation of Aβ1-42 but did not inhibit CS aggregation. This study thus identified five novel and abundant putative ECs which may play important roles in the maintenance of extracellular proteostasis, and which apparently have differing abilities to inhibit the amorphous and amyloid-forming protein aggregation pathways.
© 2021 The Protein Society.

Entities:  

Keywords:  C1r; C1s; extracellular chaperones; plasminogen activator inhibitor 3; proteostasis; prothrombin; vitronectin

Mesh:

Substances:

Year:  2021        PMID: 34553437      PMCID: PMC8521303          DOI: 10.1002/pro.4189

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  55 in total

1.  Clusterin binds by a multivalent mechanism to the Fc and Fab regions of IgG.

Authors:  M R Wilson; S B Easterbrook-Smith
Journal:  Biochim Biophys Acta       Date:  1992-10-20

Review 2.  Walking the tightrope: proteostasis and neurodegenerative disease.

Authors:  Justin J Yerbury; Lezanne Ooi; Andrew Dillin; Darren N Saunders; Danny M Hatters; Philip M Beart; Neil R Cashman; Mark R Wilson; Heath Ecroyd
Journal:  J Neurochem       Date:  2016-03-08       Impact factor: 5.372

3.  Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers.

Authors:  B V Zlokovic; C L Martel; E Matsubara; J G McComb; G Zheng; R T McCluskey; B Frangione; J Ghiso
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-30       Impact factor: 11.205

4.  Clusterin has chaperone-like activity similar to that of small heat shock proteins.

Authors:  D T Humphreys; J A Carver; S B Easterbrook-Smith; M R Wilson
Journal:  J Biol Chem       Date:  1999-03-12       Impact factor: 5.157

5.  Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system.

Authors:  Robert D Bell; Abhay P Sagare; Alan E Friedman; Gurrinder S Bedi; David M Holtzman; Rashid Deane; Berislav V Zlokovic
Journal:  J Cereb Blood Flow Metab       Date:  2006-11-01       Impact factor: 6.200

6.  Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease.

Authors:  Denise Harold; Richard Abraham; Paul Hollingworth; Rebecca Sims; Amy Gerrish; Marian L Hamshere; Jaspreet Singh Pahwa; Valentina Moskvina; Kimberley Dowzell; Amy Williams; Nicola Jones; Charlene Thomas; Alexandra Stretton; Angharad R Morgan; Simon Lovestone; John Powell; Petroula Proitsi; Michelle K Lupton; Carol Brayne; David C Rubinsztein; Michael Gill; Brian Lawlor; Aoibhinn Lynch; Kevin Morgan; Kristelle S Brown; Peter A Passmore; David Craig; Bernadette McGuinness; Stephen Todd; Clive Holmes; David Mann; A David Smith; Seth Love; Patrick G Kehoe; John Hardy; Simon Mead; Nick Fox; Martin Rossor; John Collinge; Wolfgang Maier; Frank Jessen; Britta Schürmann; Reinhard Heun; Hendrik van den Bussche; Isabella Heuser; Johannes Kornhuber; Jens Wiltfang; Martin Dichgans; Lutz Frölich; Harald Hampel; Michael Hüll; Dan Rujescu; Alison M Goate; John S K Kauwe; Carlos Cruchaga; Petra Nowotny; John C Morris; Kevin Mayo; Kristel Sleegers; Karolien Bettens; Sebastiaan Engelborghs; Peter P De Deyn; Christine Van Broeckhoven; Gill Livingston; Nicholas J Bass; Hugh Gurling; Andrew McQuillin; Rhian Gwilliam; Panagiotis Deloukas; Ammar Al-Chalabi; Christopher E Shaw; Magda Tsolaki; Andrew B Singleton; Rita Guerreiro; Thomas W Mühleisen; Markus M Nöthen; Susanne Moebus; Karl-Heinz Jöckel; Norman Klopp; H-Erich Wichmann; Minerva M Carrasquillo; V Shane Pankratz; Steven G Younkin; Peter A Holmans; Michael O'Donovan; Michael J Owen; Julie Williams
Journal:  Nat Genet       Date:  2009-09-06       Impact factor: 38.330

7.  Induction of glioma cell migration by vitronectin in human serum and cerebrospinal fluid.

Authors:  Yuji Fukushima; Masakazu Tamura; Hidemitsu Nakagawa; Kazuyuki Itoh
Journal:  J Neurosurg       Date:  2007-09       Impact factor: 5.115

8.  Immunohistochemical studies of vitronectin, C5b-9, and vitronectin receptor in membranous nephropathy.

Authors:  T Ogawa; N Yorioka; M Yamakido
Journal:  Nephron       Date:  1994       Impact factor: 2.847

9.  Urinary vitronectin identifies patients with high levels of fibrosis in kidney grafts.

Authors:  Laura Carreras-Planella; David Cucchiari; Laura Cañas; Javier Juega; Marcella Franquesa; Josep Bonet; Ignacio Revuelta; Fritz Diekmann; Omar Taco; Ricardo Lauzurica; Francesc Enric Borràs
Journal:  J Nephrol       Date:  2020-12-04       Impact factor: 3.902

Review 10.  Secreted Chaperones in Neurodegeneration.

Authors:  Kriti Chaplot; Timothy S Jarvela; Iris Lindberg
Journal:  Front Aging Neurosci       Date:  2020-08-27       Impact factor: 5.750

View more
  3 in total

1.  Expanding the family of extracellular chaperones: Identification of human plasma proteins with chaperone activity.

Authors:  Nicholas J Geraghty; Sandeep Satapathy; Megan Kelly; Flora Cheng; Albert Lee; Mark R Wilson
Journal:  Protein Sci       Date:  2021-10-04       Impact factor: 6.725

Review 2.  Clusterin, other extracellular chaperones, and eye disease.

Authors:  Mark R Wilson; Sandeep Satapathy; Shinwu Jeong; M Elizabeth Fini
Journal:  Prog Retin Eye Res       Date:  2021-12-10       Impact factor: 19.704

Review 3.  Stress-responsive regulation of extracellular proteostasis.

Authors:  Jaleh S Mesgarzadeh; Joel N Buxbaum; R Luke Wiseman
Journal:  J Cell Biol       Date:  2022-02-22       Impact factor: 10.539

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.